Skip to main content

in-situ ocular gels of Ketorolac Tromethamine


In-situ gelling systems are viscous polymer-based liquids that exhibit sol-to-gel phase transition on the ocular surface due to change in a specific physico-chemical parameter like ionic strength, temperature or pH. A major problem in ocular therapeutics is the attainment of optimal drug concentration at the site of action, which is compromised mainly due to pre-corneal loss resulting in only a small fraction of the drug being ocularly absorbed. The effective dose administered can be altered by increasing the retention time of medication into the eye by using in situ gel forming systems, thereby preventing the tear drainage. The aim of the present investigation is to prepare and evaluate novel in situ ocular gelling system (Thermo-reversible, pH induced, and ion activated in situ gelling systems) of Ketorolac tromethamine. Polymers like Pluronic F 127, Methyl cellulose, Carbopols, Sodium alginate, Xanthan gum, HPMC E50LV were used for the preparation of in situ gelling systems of Ketorolac tromethamine. The formulations were evaluated for clarity, pH measurement, gelling capacity, drug content estimation, rheological study, in vitro drug release, ocular irritation studies (as per draize test) and ex-vivo corneal permeation studies using isolated goats cornea. The developed formulations showed sustained release of drug with increased residence time. The formulations were found to be non-irritating with no ocular damage. These in situ gelling systems (Thermo-reversible, pH induced, and ion activated in situ gelling systems) may be a valuable alternative to the conventional eye drops.

Comments

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcure.co.in Rahul.Morgaonkar@emcure.co.in recruitment@em

DoE - Doctrine of Equivalents

The Doctrine of Equivalents is a legal principle that is relevant to patent law, particularly in the United States, and it helps protect inventors' rights even when minor changes or substitutions have been made to a patented invention.  When an inventor applies for a patent, the claims in the patent document define the scope of protection for the invention. These claims outline the specific elements or features of the invention that are considered unique and non-obvious. If another party copies or uses the patented invention without permission, it may be considered infringement. However, in some cases, the accused infringer may make slight modifications to the invention that fall outside the literal scope of the patented claims. The Doctrine of Equivalents comes into play here. It allows the patent holder to assert that the accused infringer's modified version is still equivalent to the patented invention and, therefore, falls within the scope of the patent protection. For the

Competitive Landscape for Pharmaceutical Generic products.

Creating a competitive landscape for a pharmaceutical generic product involves analyzing the market and identifying key players, their strengths, weaknesses, and market positioning. Here's a simplified outline: **Competitive Landscape Analysis for Pharmaceutical Generic Product:** 1. **Market Overview:**    - Size of the pharmaceutical generic product market.    - Growth trends and forecasts.    - Regulatory environment and barriers to entry. 2. **Key Players:**    - List the major pharmaceutical companies producing the generic product.    - Include both global and regional players. 3. **Market Share:**    - Percentage of market share held by each major player.    - Trends in market share changes over time. 4. **Product Portfolio:**    - Types of generic products offered by each player.    - Variations in strengths, dosage forms, and delivery methods. 5. ** Competitive Advantage :**    - Identify unique selling points of each player's products.    - Cost advantages, manufacturi